New York, USA – December 14, 2020 – DDA Platform, the mature division of Creative Bioarray, has devoted years of efforts to developing high-quality biotechnology products and services to accelerate life science research. Recently DDA Platform announced the release of its in vitro toxicology & in vivo toxicology to support the early stages of drug discovery.
Identifying potential toxicity in the early stages of drug development can save time and development costs, and most importantly, reduce the possibility of late failure. Creative Bioarray utilized primary cells from many different tissues and organs and specializes in predictive 3D tissue and cell-based in vitro toxicity assays. Before using animal models, in vitro procedures can be used to determine specific effects on cells and tissues. In vitro toxicity analysis includes applying new substances to mammalian cells that have been cultured in a single-layer 2D or biomimetic 3D structure, and monitoring their subsequent biochemical and phenotypic responses to identify cells that represent the results of toxicity.
Scientists at DDA Platform not only provide data but also provide expertise to interpret the generated data, DDA has established a network of toxicology consultants and experts in the region to provide additional support for the most challenging projects. In addition, customers can access database at any time to facilitate discussion and decision-making. The available services include but not limited to: Cytotoxicity, Cardiotoxicity, Hepatotoxicity, Nephrotoxicity, Genotoxicity, Phototoxicity.
At Creative Bioarray, in vivo toxicology services range from acute (single dose) to chronic (multi-dose) dosing regimens. Several exposure routes are available in various species such as rodents, rabbits and guinea pigs (for example, oral, intravenous, intraperitoneal, intramuscular, topical, etc.). A comprehensive toxicology assessment can be obtained through internal resources or through strategic partnerships with external suppliers. These assessments include hematology, urinalysis, clinical chemistry, histopathology, biological analysis and toxicokinetics.
“For in vitro toxicology services, Creative Bioarray is an ideal partner to help you use another set of techniques to understand the toxicity of compounds. We can help you determine which compounds have the best safety and can be applied in clinical.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Because we have advanced facilities and rich experience in preclinical research, we have the skills and expertise to accelerate the development of drug candidates, from discovery to regulatory submission.”
About DDA Platform
As a mature division of Creative Bioarray, DDA Platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.